ACTH(4-10) analogue (research nootropic peptide)
Semax
-related heptapeptide studied for BDNF and neurotrophic signalling, with clinical use in some jurisdictions as a neurometabolic agent.
Primary Mechanism of Action
Clinical / Scientific
Semax is an ACTH fragment analogue. Research describes increased BDNF/NGF expression and effects on monoaminergic systems. It has been used as a registered medicine in some countries for selected neurologic indications; that is not global approval.
Pathway Targets
BDNF signalling
Scientific explanation
Reported neurotrophic gene-expression effects.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: BDNF signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| BDNF / neurotrophins | Experimental/regional clinical neuromodulation | Plasticity signalling | Investigational (region-specific labelled use exists) |
In Plain Language
Semax is a short ACTH-like peptide studied for brain growth-factor signals. In a few countries it is a registered neurologic product; elsewhere it is still a research analogue.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.